<DOC>
	<DOCNO>NCT02489981</DOCNO>
	<brief_summary>The safety Spiriva® 2.5 µg Respimat® 60 puff ( hereinafter refer Spiriva® Respimat® ) patient severe persistent asthma real-world use confirm clinical trial .</brief_summary>
	<brief_title>Specific Use-result Surveillance Spiriva Respimat Asthmatics</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criterion : Patients diagnose severe persistent bronchial asthma Patient age &gt; = 15 year Patients naive Spiriva Respimat receive Spiriva Respimat first time treatment bronchial asthma top least ICS ( Inhaled corticosteroid ) treatment . Exclusion criterion : Patients contraindication Spiriva Respimat define package insert Spiriva Respimat Patients enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>